NYPOZI (filgrastim-txid)
LEUKOCYTE STIMULATING FACTORS·SEVERE CHRONIC NEUTROPENIA·+9
CIPLA USA, INC.
Indication
Neutropenia secondary to AML treatment
Neutropenia secondary to acute myeloid leukemia (AML) treatment is an acquired hematologic complication characterized by a critical reduction in circulating absolute neutrophil counts resulting from antineoplastic therapy. Read more about Neutropenia secondary to AML treatment
11 drugs 8 manufacturers
Drugs that treat it
Common Neutropenia secondary to AML treatment therapies.
FILKRI (filgrastim-laha)
LEUKOCYTE STIMULATING FACTORS·SEVERE CHRONIC NEUTROPENIA·+7
ACCORD BIOPHARM
Filter & compare in the drug finder →Opens the drug finder with Neutropenia secondary to AML treatment preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonNeutropenia secondary to acute myeloid leukemia (AML) treatment is an acquired hematologic complication characterized by a critical reduction in circulating absolute neutrophil counts resulting from antineoplastic therapy.
It predominantly affects the hematopoietic and immune systems of patients undergoing intensive induction or consolidation chemotherapy, targeted therapies, or hypomethylating regimens for AML.
Pathophysiologically, cytotoxic and myelosuppressive agents transiently ablate rapidly dividing myeloid progenitor cells within the bone marrow, exacerbating preexisting disease-related marrow failure.
Clinically, this state manifests as profound and often prolonged immunosuppression, markedly elevating patient vulnerability to severe, potentially life-threatening bacterial and invasive fungal infections.
- ajmc.com
Neutropenia secondary to acute myeloid leukemia (AML) treatment is an acquired hematologic complication characterized by a critical reduction in circulating absolute neutrophil counts resulting from antineoplastic therapy Pathophysiologically, cytotoxic and myelosuppressive agents transiently ablate rapidly dividing myeloid progenitor cells within the bone marrow, exacerbating preexisting disease-related marrow failure Clinically, this state manifests as profound and often prolonged immunosuppre...
- msdmanuals.com
Neutropenia secondary to acute myeloid leukemia (AML) treatment is an acquired hematologic complication characterized by a critical reduction in circulating absolute neutrophil counts resulting from antineoplastic therapy Pathophysiologically, cytotoxic and myelosuppressive agents transiently ablate rapidly dividing myeloid progenitor cells within the bone marrow, exacerbating preexisting disease-related marrow failure
- ajmc.com
It predominantly affects the hematopoietic and immune systems of patients undergoing intensive induction or consolidation chemotherapy, targeted therapies, or hypomethylating regimens for AML Clinically, this state manifests as profound and often prolonged immunosuppression, markedly elevating patient vulnerability to severe, potentially life-threatening bacterial and invasive fungal infections
- ashpublications.org
It predominantly affects the hematopoietic and immune systems of patients undergoing intensive induction or consolidation chemotherapy, targeted therapies, or hypomethylating regimens for AML
- neupogenhcp.com
It predominantly affects the hematopoietic and immune systems of patients undergoing intensive induction or consolidation chemotherapy, targeted therapies, or hypomethylating regimens for AML
Personalize your experience
Follow Neutropenia secondary to AML treatment and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.